Pirfenidone Alleviates Against Fine Particulate Matter-Induced Pulmonary Fibrosis Modulating via TGF-β1/TAK1/MKK3/p38...

Area of Science:

• Environmental Health
• Pulmonary Medicine
• Pharmacology

Background:

• Particulate matter (PM) air pollution is a significant cause of lung inflammation, respiratory disease, and mortality.
• Idiopathic pulmonary fibrosis is treated with pirfenidone, an anti-fibrotic agent.

Purpose of the Study:

• To investigate the therapeutic potential of pirfenidone in mitigating pulmonary fibrosis induced by PM exposure.
• To elucidate the molecular mechanisms underlying pirfenidone's protective effects against PM-induced lung injury.

Main Methods:

• Pulmonary fibrosis was induced in rats via intratracheal instillation of PM10.
• Pirfenidone (200 and 400 mg/kg) was administered orally every other day for 30 days post-PM10 exposure.
• Lung injury, fibrosis scores, pro-inflammatory cytokines, and fibrosis-related markers were assessed.

Main Results:

• PM10 exposure led to significant lung injury, increased fibrosis, and elevated pro-inflammatory cytokines.
• Pirfenidone treatment suppressed key signaling pathways, including TGF-β-activated kinase 1, MAPK, and p38.
• Pirfenidone reduced the expression of fibrosis markers such as fibronectin, type 1 collagen, CTGF, and hydroxyproline.

Conclusions:

• Pirfenidone demonstrates significant therapeutic efficacy against PM-induced pulmonary fibrosis.
• The drug alleviates lung fibrosis by inhibiting inflammatory and fibrotic signaling pathways.
• Pirfenidone represents a potential therapeutic strategy for managing air pollution-related lung diseases.